Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Acute ITP (R-ITP)
NCT00372892Phase 2Completed
- Sponsor
- Hamilton Health Sciences
- Start
- Sep 2006
- Primary completion
- Dec 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in immune thrombocytopenic purpura (ITP) comparing Rituximab with Placebo (2 arms). Primary endpoints: Feasibility of recruitment at 3 years, Degree of adherence to the study protocol at 3 years and 3 more. Started Sep 2006; status: completed.
02
Drugs
rituximab
03
Conditions
immune thrombocytopenic purpura (ITP)
Beyond the preview
Go deeper on NCT00372892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00372892.